256 related articles for article (PubMed ID: 30912099)
1. Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics.
Sookoian S; Pirola CJ
Semin Liver Dis; 2019 May; 39(2):124-140. PubMed ID: 30912099
[TBL] [Abstract][Full Text] [Related]
2. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system.
Pirola CJ; Salatino A; Sookoian S
World J Gastroenterol; 2021 Jan; 27(4):305-320. PubMed ID: 33584064
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional networks implicated in human nonalcoholic fatty liver disease.
Ye H; Liu W
Mol Genet Genomics; 2015 Oct; 290(5):1793-804. PubMed ID: 25851235
[TBL] [Abstract][Full Text] [Related]
5. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic mechanisms of NASH.
Eslam M; George J
Hepatol Int; 2016 May; 10(3):394-406. PubMed ID: 26683320
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
8. Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis.
Kozlitina J
Gastroenterol Clin North Am; 2020 Mar; 49(1):25-44. PubMed ID: 32033763
[TBL] [Abstract][Full Text] [Related]
9. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.
Kawaguchi T; Shima T; Mizuno M; Mitsumoto Y; Umemura A; Kanbara Y; Tanaka S; Sumida Y; Yasui K; Takahashi M; Matsuo K; Itoh Y; Tokushige K; Hashimoto E; Kiyosawa K; Kawaguchi M; Itoh H; Uto H; Komorizono Y; Shirabe K; Takami S; Takamura T; Kawanaka M; Yamada R; Matsuda F; Okanoue T
PLoS One; 2018; 13(1):e0185490. PubMed ID: 29385134
[TBL] [Abstract][Full Text] [Related]
10. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population.
Rabelo F; Stefano JT; Cavaleiro AM; Lima RVC; de Campos Mazo DF; Carrilho FJ; Correa-Giannella ML; Oliveira CP
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):330-335. PubMed ID: 30087027
[TBL] [Abstract][Full Text] [Related]
11. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
Moore JB
Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
Carr RM; Oranu A; Khungar V
Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
[TBL] [Abstract][Full Text] [Related]
13. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
Anstee QM; Day CP
Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
[TBL] [Abstract][Full Text] [Related]
14. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
15. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
[TBL] [Abstract][Full Text] [Related]
16. Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes.
Liu XL; Ming YN; Zhang JY; Chen XY; Zeng MD; Mao YM
Exp Mol Med; 2017 Jan; 49(1):e283. PubMed ID: 28082742
[TBL] [Abstract][Full Text] [Related]
17. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
[TBL] [Abstract][Full Text] [Related]
19. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis.
Kanwar P; Kowdley KV
Clin Liver Dis; 2016 May; 20(2):225-43. PubMed ID: 27063266
[TBL] [Abstract][Full Text] [Related]
20. Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease.
Cespiati A; Youngson NA; Tourna A; Valenti L
Curr Pharm Des; 2020; 26(10):998-1009. PubMed ID: 31969087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
